KEY DETAILS
Novo Nordisk's next-generation drug CagriSema showed significant weight loss in a major late-stage trial this week.
A growing number of lawsuits claim GLP-1 drugs caused permanent eye damage and vision loss in patients.
Plaintiffs are now suing over Ozempic, Wegovy, and Zepbound, asking whether these drugs can cause blindness.
Ascendis Pharma has ended its partnership with Novo Nordisk to take full control of its TransCon metabolic pipeline.
Additional lawsuits allege that Ozempic and other GLP-1 medications may cause sudden, unexpected vision loss.
Novo Nordisk's next-generation obesity drug CagriSema posted significant weight loss results in a Phase 3 trial this week, giving the company a strong data point heading into a competitive year. At the same time, a growing number of lawsuits are accusing GLP-1 drugs, including Ozempic, Wegovy, and Zepbound, of causing permanent eye damage and even blindness. Ascendis Pharma has also cut ties with Novo Nordisk to take full control of its own metabolic drug pipeline. Patients weighing these drugs and investors watching the sector have reasons to pay attention.
This week's Phase 3 results are a significant moment for Novo Nordisk, since CagriSema is the drug the company is counting on to lead its next generation of obesity treatments. The trial showed significant weight loss among patients who took the drug, which gives Novo Nordisk a strong result to bring into ongoing regulatory conversations. For patients and doctors watching the pipeline, this data offers an early signal of what CagriSema might offer once it becomes available. The company still has more steps ahead before the drug reaches the market, but a positive late-stage readout puts it on stronger footing than before.
The same week also brought different news for GLP-1 drugs already on the market. A growing number of lawsuits now claim these medications caused permanent eye damage and vision loss in patients who took them. The suits describe patients experiencing lasting harm to their eyesight after starting treatment, and attorneys say more cases are being filed as awareness spreads. For patients currently on these medications, the lawsuits are a reminder to discuss any changes in vision with their doctor promptly.
Some of these lawsuits name Ozempic, Wegovy, and Zepbound specifically, and they raise a direct question: can these drugs cause blindness? The cases are still working through the legal system, and no court has yet settled the broader question of whether GLP-1 drugs are responsible for the vision problems described. Still, the fact that plaintiffs are asking this question in court adds pressure on manufacturers to address it directly, rather than leave it as a matter of anecdotal reports. Patients who rely on these drugs for weight loss or diabetes management may want to follow how these cases develop.
While Novo Nordisk manages both the promise of CagriSema and the legal questions surrounding its established drugs, one of its former partners is moving in a different direction. Ascendis Pharma has ended its partnership with Novo Nordisk and taken full control of its TransCon metabolic pipeline. The move gives Ascendis complete ownership over the direction of these programs, without needing to coordinate with or share decisions with Novo Nordisk going forward. For a company that had been developing its metabolic drugs alongside a much larger partner, taking full control marks a shift toward greater independence in how it brings future treatments to patients.
The legal questions facing GLP-1 drugs are not limited to one set of cases. A separate wave of lawsuits alleges that Ozempic and other GLP-1 medications may cause sudden, unexpected vision loss, distinct from the permanent eye damage claims described earlier this week. These filings add to a broader pattern of litigation that manufacturers will need to respond to as more cases accumulate. Patients considering or currently using these medications may want to stay informed as these claims move through the courts, even though no findings have been established yet.
Taken together, these developments show two things happening in the GLP-1 category at once. New treatments continue to advance through clinical trials, while the drugs already on pharmacy shelves face growing legal scrutiny over their side effects. Readers who use GLP-1 medications should keep track of both threads, particularly any updates about vision changes, and talk with their doctor if they notice anything unusual after starting treatment. Investors and patients alike will likely see more news on both fronts before the year is out.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.